Herbert Helander
Corporate Officer/Principal chez The University of Alabama
Profil
Herbert Helander is the founder of Calabar AB, which was founded in 1999.
He held the title of Director at Calabar AB.
Currently, Dr. Helander holds the position of Senior Advisor-Research at AstraZeneca AB, and the position of Professor at both The University of Alabama and the University of California, Berkeley.
Previously, he held the position of Professor at the University of Oklahoma from 2000 to 2012.
Postes actifs de Herbert Helander
| Sociétés | Poste | Début |
|---|---|---|
| The University of Alabama | Corporate Officer/Principal | 01/12/2009 |
| University of California, Berkeley | Corporate Officer/Principal | 01/12/2009 |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | 01/12/2009 |
Anciens postes connus de Herbert Helander
| Sociétés | Poste | Fin |
|---|---|---|
| University of Oklahoma | Corporate Officer/Principal | - |
Calabar AB
 Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Calabar AB
Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Health Technology |